Connor, Clark & Lunn Investment Management Ltd. Legend Biotech Corp Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$38.8 - $55.46 $680,358 - $972,491	-17,535 Reduced 72.67%	6,596 $329,000
Q3 2022 Nov 10, 2022	BUY	$38.15 - $57.1 $332,935 - $498,311	8,727 Added 56.65%	24,131 $985,000
Q2 2022 Aug 05, 2022	BUY	$33.54 - $55.0 $131,510 - $215,655	3,921 Added 34.15%	15,404 $847,000
Q1 2022 May 12, 2022	BUY	$31.02 - $48.18 $356,202 - $553,250	11,483 New	11,483 $417,000

Others Institutions Holding LEGN

# of Institutions

198

Shares Held

74.2M

Call Options Held

374K

Put Options Held

387K

Price T Rowe Associates Inc Baltimore, MD

11.5M
Shares

$558 Million
0.06% of portfolio
Ra Capital Management, L.P. Boston, MA

7.51M
Shares

$364 Million
5.01% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

6.64M
Shares

$322 Million
7.6% of portfolio
Black Rock Inc. New York, NY

5.72M
Shares

$278 Million
0.01% of portfolio
Westfield Capital Management CO LP Boston, MA

4.77M
Shares

$232 Million
1.06% of portfolio

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $8.12B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account